APA

Berger A. K., von Gall C., Abel U., Delorme S., Kloor M., Ose J., Weber T. F., Stange A., Haag G. M., Haberkorn U., Lordick F. & Jäger D. (20120827). A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. : BMC cancer.

Chicago

Berger Anne Katrin, von Gall Carl, Abel Ulrich, Delorme Stefan, Kloor Matthias, Ose Jennifer, Weber Tim Frederik, Stange Annika, Haag Georg Martin, Haberkorn Uwe, Lordick Florian and Jäger Dirk. 20120827. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. : BMC cancer.

Harvard

Berger A. K., von Gall C., Abel U., Delorme S., Kloor M., Ose J., Weber T. F., Stange A., Haag G. M., Haberkorn U., Lordick F. and Jäger D. (20120827). A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. : BMC cancer.

MLA

Berger Anne Katrin, von Gall Carl, Abel Ulrich, Delorme Stefan, Kloor Matthias, Ose Jennifer, Weber Tim Frederik, Stange Annika, Haag Georg Martin, Haberkorn Uwe, Lordick Florian and Jäger Dirk. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. : BMC cancer. 20120827.